e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Cystic fibrosis: understanding a complex disease
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis
Z. Sarah, B. Sansom, E. H. Baker (London, United Kingdom)
Source:
Annual Congress 2009 - Cystic fibrosis: understanding a complex disease
Session:
Cystic fibrosis: understanding a complex disease
Session type:
E-Communication Session
Number:
463
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Z. Sarah, B. Sansom, E. H. Baker (London, United Kingdom). Lack of therapeutic potential for topical metformin in treatment of airway secretion dehydration in cystic fibrosis. Eur Respir J 2009; 34: Suppl. 53, 463
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Impact of Dexamethasone on pathogen profile of COVID-19 patients requiring intensive care: a multicentre retrospective study
Muscle energy techniques for COPD patients: Effects on pulmonary function and activities of daily living
Related content which might interest you:
Potential therapeutic use of 12-Lipoxygenase inhibitors in the treatment of mucus overproduction in cystic fibrosis
Source: Research Seminar 2009 - Molecular and Cellular aspects of Chronic Lung Disease
Year: 2009
Dose-finding and 24-h monitoring for efficacy and safety of aerosolized Nacystelyn in cystic fibrosis
Source: Eur Respir J 2002; 19: 294-302
Year: 2002
Possible mechanisms of action of azithromycin in cystic fibrosis
Source: Annual Congress 2005 - Cystic fibrosis lung disease: pieces of the puzzle
Year: 2005
Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis
Source: Eur Respir J , 49 (3) 1600987; DOI: 10.1183/13993003.00987-2016
Year: 2017
RhDNase after airway clearance therapy improves peripheral airway patency in children with cystic fibrosis
Source: Annual Congress 2006 - Cystic fibrosis lung disease: molecules images and drugs
Year: 2006
Efficacy and safety of oral sildenafil in cystic fibrosis childrenwith mild to moderate lung disease
Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis
Year: 2020
Novel antiviral properties of azithromycin in cystic fibrosis airway epithelial cells
Source: Eur Respir J 2015; 45: 428-439
Year: 2015
The effect of inhaled steroids on bronchial hyperreactivity, oxidative status, clinical and inflammatory paramerters in patients with cystic fibrosis
Source: Annual Congress 2007 - Cystic fibrosis: the balance between treatment and side-effects
Year: 2007
Treatment of cystic fibrosis airway cells with CFTR modulators reverses aberrant mucus properties
via
hydration
Source: Eur Respir J, 59 (2) 2100185; 10.1183/13993003.00185-2021
Year: 2022
An anti-inflammatory effect of azithromycin in cystic fibrosis
Source: Annual Congress 2010 - New aspects of cystic fibrosis
Year: 2010
Recommended shielding against SARS-CoV-2 impacts physical activity levels and adherence to airway clearance therapy in patients with cystic fibrosis
Source: Virtual Congress 2021 – Cystic fibrosis in children: various aspects
Year: 2021
Pharmacological treatment of the biochemical defect in cystic fibrosis airways
Source: Eur Respir J 2001; 17: 1314-1321
Year: 2001
Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis
Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017
Year: 2018
Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies
Source: Eur Respir J 2017; 49(1): 1600903; DOI: 10.1183/13993003.00903-2016
Year: 2017
Use of a new feedback tool to optimize inhaled aerosol therapy in patients with cystic fibrosis
Source: Eur Respir J 2006; 28: Suppl. 50, 261s
Year: 2006
Role of CF ion transport defect in airway inflammation and implication for antiinflammatory therapies
Source: Research Seminar 2012 - Pulmonary inflammation in paediatric respiratory disease
Year: 2012
GED-0507 as a novel anti-fibrotic treatment option for pulmonary fibrosis
Source: International Congress 2018 – Regenerative and anti-fibrotic approaches
Year: 2018
Efficacy of low-dose, long-term clarithromycin administration in improving the clinical course in cystic fibrosis patients with chronic
P. aeruginosa
airway colonization
Source: Eur Respir J 2003; 22: Suppl. 45, 514s
Year: 2003
Inhaled mannitol as treatment for children with cystic fibrosis
Source: Annual Congress 2008 - The use of inhaled mannitol for assessing airway disease
Year: 2008
Inhaled phosphodiesterase type 5 inhibitors restore chloride transport in cystic fibrosis mice
Source: Eur Respir J 2011; 37: 72-78
Year: 2011
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept